Use

Prospera Transplant Assessment is a non‑invasive blood test that measures the fraction of donor‑derived cell‑free DNA (dd‑cfDNA) in the recipient’s blood using SNP‑based massively multiplexed PCR technology, without requiring prior donor or recipient genotyping. It is intended to help assess the risk of active transplant rejection—such as antibody‑mediated or T cell‑mediated rejection—by aiding providers in ruling in or out rejection and guiding the need for diagnostic testing or biopsy in kidney transplant recipients. The test has been clinically and analytically validated regardless of donor relatedness, rejection type, and clinical presentation, and has been shown to predict rejection up to two to five months before biopsy‑proven events in the ProActive study registry. The test is not FDA‑cleared or approved and is performed in a CLIA‑certified, CAP‑accredited laboratory.